News Headlines

  1. Shantha Biologics Announces Cartridge Fill-Finish Collaboration 7/3/2026

    Shantha Biologics today announced that it has entered into an outsourcing agreement with Novo Nordisk to provide cartridge fill-finish manufacturing services in India.

  2. Bora Pharmaceuticals Completes Acquisition Of MacroGenics' Rockville Manufacturing Operations For $122.5M 7/2/2026

    Bora Pharmaceuticals Co., Ltd. today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5M through its wholly owned subsidiary Bora Biologics USA, LLC.

  3. Arcturus Therapeutics Announces Strategic Collaboration With Thermo Fisher Scientific To Advance ARCT-032 For Cystic Fibrosis 7/2/2026

    Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis.

  4. Prestige Biopharma Enters Strategic MOU With Charles River, A Global Contract Research Organization 7/2/2026

    Prestige Biopharma Limited, a global biopharmaceutical company, announced today that it has signed a strategic Memorandum of Understanding (MOU) with Charles River Laboratories International, Inc., a premier global life sciences company headquartered in Massachusetts, U.S., to collaborate on the development, testing, analysis, and manufacturing of biopharmaceuticals.

  5. Junshi Biosciences Enters Licensing Collaboration With Fosun Wanbang On Roconkibart (IL-17A) 7/1/2026

    Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the company has recently entered into a license agreement with Fosun Wanbang Pharma Group (“Fosun Wanbang,” a wholly-owned subsidiary of Fosun Pharma (HKEX: 02196; SSE: 600196).

  6. Samsung Bioepis Relaunches BYOOVIZ (ranibizumab-nuna) In The United States In Partnership With Harrow 7/1/2026

    Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ (ranibizumab-nuna) in the United States (US), in partnership with Harrow.

  7. Lonza Expands Strategic Collaboration With Leading US Biopharmaceutical Company 7/1/2026

    Lonza, the world’s leading contract development and manufacturing organization (CDMO), today announced an expanded strategic collaboration with a leading US-based biopharmaceutical company.

  8. Lonza Expands HPAPI Capacity In Visp, Further Supporting Its Position In Payload-Linker Manufacturing 6/30/2026
  9. AustinPx Expands KinetiSol™ Technology Commercial Access Through Thermo Fisher Scientific Collaboration 6/30/2026

    AustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement for orally delivered small molecule drugs, today announced its agreement with Thermo Fisher Scientific’s Patheon pharma services for the installation of AustinPx’s KinetiSol™ Technology equipment.

  10. Ratio Therapeutics Enters Strategic Actinium-225 Supply Agreement With PanTera To Support Radiopharmaceutical Development Programs 6/30/2026

    Ratio Therapeutics Inc. (Ratio), a clinical-stage pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced that it has entered into a strategic supply agreement with PanTera, an innovative producer scaling the supply of vital medical radionuclides, supporting Ratio’s ongoing efforts to build a robust and scalable supply infrastructure for its radiopharmaceutical development programs.